MolMed S.p.A. is a medical biotechnology company focused on discovery, R&D, and clinical validation of innovative therapies for the treatment of cancer (two therapies in phase III)
Molmed’s cancer pipeline:
Cell-based therapy in Phase III for high-risk leukaemia. TK enabling safe haploidentical haematopoietic stem cell transplantation (HSCT) for the treatment of haematological malignancies.
Usa and Europe Approval by the 2013 (maybe 2012)
A novel VTA for the treatment of solid tumours. Phase III trial in mesothelioma ongoing. Randomised Phase II trials ongoing in non-small-cell lung cancer, ovarian cancer, soft tissue sarcomas and mesothelioma as maintenance treatment. Completed Phase II trials in colorectal cancer, liver cancer and small-cell lung cancer.
Usa and Europe Approval by the 2013
Molmed has got a strong positive financial position to support product development and won’t need any capital increase in the next years